TL;DR
This paper introduces a novel near-infrared (NIR) fluorophore that can emit light at two distinct wavelengths (~700 nm and ~800 nm) from a single molecule. This dual-color capability was demonstrated in vivo for lymph node mapping in a porcine model and is compatible with existing clinical fluorescence imaging systems, offering a promising advancement for surgical guidance.
What Problem Does This Paper Address?
Accurate identification of lymph nodes is crucial in cancer surgery, particularly for staging and determining the extent of disease spread. Current fluorescence-guided surgery relies on a limited number of approved agents, primarily Indocyanine Green (ICG), which emits in the NIR spectrum. While effective, ICG has limitations, and there's a need for new agents that offer enhanced capabilities, such as dual-color imaging. Dual-color imaging could provide more detailed information about tissue structures and lymphatic pathways, improving surgical precision and potentially reducing complications. The challenge lies in developing a single, biocompatible fluorophore that can emit at two distinct NIR wavelengths, mimicking the spectral ranges of existing clinically relevant dyes like ICG and Methylene Blue, without requiring multiple agents or complex formulations.
Methods
The core innovation lies in the design and synthesis of a novel BF<sub>2</sub>-azadipyrromethene (NIR-AZA) fluorophore, designated as 1. This molecule was engineered to be amphiphilic, possessing both hydrophilic (sulfonic acid groups) and hydrophobic (phenyl rings) regions. This structural design allows the fluorophore to exist in two distinct states in aqueous solutions: isolated molecular form and aggregated (J-aggregate) form.
- Synthesis: The NIR-AZA fluorophore 1 was synthesized through a multi-step process, culminating in the attachment of sulfonic acid groups via reaction with 1,4-butane sultone.
- Characterization: The aggregation behavior and spectral properties of fluorophore 1 were thoroughly investigated using UV-Vis spectroscopy and Transmission Electron Microscopy (TEM). This confirmed the formation of distinct molecular and aggregate species with different optical properties.
- Toxicity Assessment: A preclinical toxicology study was conducted in Sprague-Dawley rats to evaluate the safety of fluorophore 1 following intravenous administration at a high dosage over seven consecutive days.
- In Vivo Imaging: The dual-color imaging capabilities were demonstrated in a large-animal porcine model for lymph node mapping. This involved injecting the fluorophore and imaging the lymphatic system and lymph nodes using both preclinical and clinical fluorescence imaging systems. Ex-vivo human tissue specimens were also used for imaging.
Datasets
Not explicitly discussed in the paper as distinct datasets. The study relies on spectral data obtained from the synthesized fluorophore under various conditions (DMSO, water, PBS, PBS/Kolliphor EL) and imaging data acquired from animal models and human tissue.
Key Insights and Ideas
- Single Molecule, Dual Emission: The most significant insight is the successful creation of a single fluorophore molecule capable of emitting at two distinct NIR wavelengths (~700 nm and ~800 nm) by controlling its aggregation state. This is achieved by leveraging the interplay between its molecular and J-aggregate forms.
- Aggregation-Induced Emission Shift: The J-aggregate form of the fluorophore exhibits a substantial bathochromic shift (red-shift) in its emission spectrum, moving from the ~700-730 nm range (molecular form) to the ~799-822 nm range (aggregate form). This shift is crucial for achieving dual-color imaging.
- Biocompatibility and Stability: The amphiphilic design of the fluorophore ensures its stability in aqueous solutions, a critical requirement for biomedical applications. Furthermore, the in vivo studies demonstrated its stability within the complex biological environment of lymphatic tissue.
- Clinical Compatibility: The fluorophore was successfully imaged using existing clinical fluorescence-guided surgery instruments (Karl Storz and Stryker), indicating a straightforward path for clinical translation without requiring specialized new hardware.
- Excellent Safety Profile: The preclinical toxicity study revealed no significant adverse effects, even at high doses, suggesting a favorable safety profile for clinical use.
Key Results
- Dual Emission Achieved: The NIR-AZA fluorophore 1 demonstrated dual emissions at approximately 700 nm (molecular form) and 800 nm (aggregated form).
- Lymph Node Mapping Success: Dual-color fluorescence imaging of lymph node mapping was successfully performed in a large-animal porcine model. The injection site, lymphatic channels, and lymph nodes were clearly visualized at both 700 nm and 800 nm.
- Ex Vivo Human Tissue Imaging: The fluorophore was also effective for lymph node mapping in ex-vivo human colorectal tissue.
- No Observed Toxicity: The rat toxicology study showed no significant adverse effects or organ damage at the tested dosage, establishing a No Observable Adverse Effect Level (NOAEL) of 2 mg/kg/day.
- Compatibility with Clinical Systems: Imaging was successfully performed using clinical instruments, demonstrating the practical applicability of the fluorophore.
Limitations and Future Work
- Microscope Limitations for Live Cell Imaging: While live cell imaging showed intracellular fluorescence and membrane staining, the study was limited by microscope hardware, preventing fluorescence detection at 800 nm. Future work could explore this further.
- Further Clinical Translation: While promising, the study is preclinical. Further clinical trials are necessary to fully establish the efficacy and safety of this fluorophore in human patients.
- Optimization for Specific Applications: The authors suggest that the formulation and concentration of the fluorophore can be optimized for specific surgical applications to maximize its utility.
- Exploration of Other Aggregates: The paper focuses on J-aggregates. Further research could explore other types of aggregates and their spectral properties.
Summary updated